ArticleBMC pediatrics2025
Application of HRCT-based radiomics to predict interstitial lung disease for juvenile dermatomyositis.
Article in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- High-resolution computed tomography assessment of connective tissue disease-associated interstitial lung disease: Advances in diagnosis and prognostic evaluation.World journal of radiology · 2026Review
- Integration of clinical variables and CT radiomics features in a nomogram for predicting interstitial lung disease in Sjögren's syndrome.Journal of thoracic disease · 2026Article
- Imaging Findings of Pediatric Rheumatic Disorders: JIA in the PRINTO Era and Autoimmune Interferonopathies.Pediatrics international : official journal of the Japan Pediatric SocietyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundInterstitial lung disease (ILD) is a frequently observed pulmonary manifestation in juvenile dermatomyositis (JDM), and may significantly impact patient outcomes. Therefore, early lung involvement identification is essential. Radiomics is a new image analysis technique and might offer valuable information for the diagnosis of interstitial lung disease in juvenile dermatomyositis (JDM-ILD).
methodsWe retrospectively analyzed clinical data of 56 children with JDM, and all participants gave written informed consent. These children were divided into the JDM group (n = 32) and JDM-ILD group (n = 24) based on chest high-resolution CT (HRCT). The lung intelligence kit (LK) software was used to outline the bilateral lung tissue structure automatically. The radiomics score combining with clinical variables was used to establish a prediction model for JDM-ILD.
resultsA total of seven radiomics features including the maximum, mean, skewness, and kurtosis features for the First Order Features, the InverseVariance feature for the Gray Level Co-occurrence Matrix (GLCM) Features, the Size Zone NonUniformity Normalized feature for the Gray Level Size Zone Matrix(GLSZM)Features, and the Run Entropy feature for the Gray Level Run Length Matrix (GLRLM) Features were identified. The multivariable logistic regression revealed that anti-MDA5 antibody and radiomics score showed a significant correlation with the development of ILD in children with JDM. The combined prediction model based on radiomics score and anti-MDA5 antibody achieved good performance in predicting JDM-ILD in the training (0.92, 95% CI 0.82-1.00) and validation (0.93, 95% CI 0.83-1.00) groups.
conclusionThe nomogram combining radiomics and clinical variables achieved an optimal prediction of ILD in children with JDM. This approach may facilitate earlier detection of pulmonary involvement, support individualized risk stratification, and guide more proactive therapeutic interventions. Future studies should aim to validate this model in larger, prospective, and multicenter cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.